Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Breast, Ovarian, and Gastric Cancers
NCT03342417Phase 2Terminated
- Sponsor
- ExcellaBio
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in breast cancer, ovarian cancer and gastric cancer (GC) (3 arms), sponsored by ExcellaBio. Primary endpoints: Number of participants with treatment-related adverse events at 1 year and Clinical Response at 2 years. Started Feb 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
breast cancerovarian cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03342417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342417.